T
he Drm (also known as Gremlin), a 184-aa protein initially identified through differential screening as a transcriptional down-regulated gene in v-mos-transformed rat embryonic fibroblasts (1) , belongs to the Dan family of secreted glycosylated proteins (2, 3) , which contains a highly conserved cysteine knot domain shared by the TGF␤ superfamily, PDGF, nerve growth factor, and other secreted proteins (4) . Drm and Dan regulate early development (5) (6) (7) (8) , tumorigenesis (1, 9, 10) , and renal pathophysiology (11) . The action of Drm and Dan on development and possibly diabetic nephropathy is mediated by heterodimerizing with certain bone morphogenic proteins (BMPs), 4 in particular BMP2, 4, and 7 (2, 3, 11, 12) to subsequently block the ability of BMPs to bind their receptors (2, 12, 13) . We have previously shown that the capacity of Drm to suppress transformation and tumorigenesis (1, 9, 10 ) is mediated by a mechanism that is independent of BMPs and involves both up-regulation of p21
Cip1 and down-regulation of p42/44 MAPK (9) , suggesting additional target(s) for Drm and other Dan family members.
To identify additional target proteins for Drm and other Dan family members, we used a yeast two-hybrid screening approach with a Drm-GAL4 fusion construct as the bait to search for potential Drm-binding partners. This approach identified Slit as one type of the Drm-interacting proteins. We further characterized the interaction of Drm and Dan with Slit proteins and found that both Drm and Dan could inhibit monocyte migration induced by chemotactic factors. Thus, the data demonstrate for the first time that Drm and Dan physically and functionally interact with Slit proteins to act as a negative regulator for monocyte chemotaxis.
Materials and Methods

Yeast two-hybrid screening
The HybriZAP2.1 two-hybrid system (Stratagene, La Jolla, CA) was performed based on the protocol provided by the manufacturer. Briefly, yeast cells (YRG2) cotransfected with Drm-GAL4-BD bait plasmid and a 19-day postcoitum rat fetal kidney cDNA-GAL4-AD expression library were selected on HLT medium. Plasmids from surviving colonies expressing ␤-galactosidase were rescreened, sequenced, and BLAST-searched against GenBank.
Plasmids, Abs, reagents, and cell lines
pMex, pMex-Drm, pMex-HA-Drm, pMex-Drm*, and rabbit anti-Drm were previously described (2) . Plasmids encoding Slit1-myc and its empty vector pCs2 were originally obtained from Dr. D. M. Ornitz. Anti-myc Ab and its agarose conjugate and anti-hemagglutinin Ab and its agarose conjugate were from Santa Cruz Biotechnology (Santa Cruz, CA). Recombinant mouse Dan, anti-Dan-neutralizing Ab, recombinant BMP 2 and 4 were obtained from R&D Systems (Minneapolis, MN). Recombinant human stromal cell-derived factor 1␣ (SDF-1␣) was purchased from PeproTech (Rocky Hill, NJ).
125 I-SDF-1␣ with a specific radioactivity of 2000 Ci/mmol was obtained from Amersham Life Science (Cleveland, OH).
HEK 293 and HT1080 cells, acquired from American Type Culture Collection (Manassas, VA), were maintained in DMEM supplemented with 10% FBS (Invitrogen Life Technologies, Carlsbad, CA). To generate cell lines stably expressing Drm and/or Slit, corresponding expression plasmids were transfected into HEK293 or HT1080 cells by using Effectene Transfection Reagent (Qiagen, Valencia, CA). After 48 h, transfected cells were selected and maintained in the presence of geneticin (400 g/ml).
To purify Drm for chemotaxis assay, 10 ml of conditioned medium from Drm expression cells or its vector control cells was incubated with 1 ml of prewashed heparin-acrylic beads (Sigma-Aldrich, St. Louis, MO) for 2 h at 4°C. After washing three times with PBS, proteins were eluted by 10 mM Tris (pH 8.0)/ 1.5 M NaCl, desalted, and concentrated to 0.3 ml for both Drm and control.
Immunoprecipitation and immunoblotting
For cotransfection assay, indicated plasmids were transiently transfected into HEK 293 cells. Cells were harvested 48 h later and lysed in radioimmunoprecipitation assay buffer. For coculture assay, indicated stable cell lines were mixed (1:1) and the conditioned supernatants were harvested after 72 h of culture. For immunoprecipitation (IP), 10 g of primary Ab agarose conjugate was added to lysates or conditioned supernatants and incubated at 4°C for 4 h. Beads were washed five times in radioimmunoprecipitation assay buffer. Immunoblotting (IB) was performed as previously described after SDS-PAGE and transfer (2) .
Chemotaxis assay
Human PBMC were isolated by Ficoll density gradient centrifugation from leukopacks supplied by the Department of Transfusion Medicine (Clinical Center, National Cancer Institute (NCI), Bethesda, MD) with the approval of the NCI Human Research Committee. Monocytes were purified (Ͼ90%) from human PBMC by Percoll density gradient centrifugation (14) with all solutions prepared in endotoxin-free water. Monocyte chemotaxis was assessed using a 48-well microchemotaxis chamber assay (14) with minor modifications. Briefly, diluted SDF-1␣ and monocyte suspension (10 6 cells/ml) were, respectively, placed in the lower and upper wells of a chamber (NeuroProbe, Gaithersburg, MD), which were separated by a 5-m polycarbonate filter (NeuroProbe). To test their effect on monocyte chemotaxis, Slit, Drm, Dan, and/or Ab were added to the lower or upper wells as indicated. Monocytes were suspended in and all factors were diluted with chemotaxis medium (RPMI 1640 containing 1% BSA). After incubation at 37°C in humidified air with 5% CO 2 for 1.5 h, the filters were removed and stained, and the cells migrating across the filter were counted. The results are presented as number of cells per high-power field.
Binding assay
Competitive binding was performed in triplicate by adding a constant amount of 125 I-SDF-1␣ and increasing amounts of unlabeled SDF-1␣ or Dan to individual 1.5-ml microfuge tubes, each containing 10 6 monocytes suspended in RPMI 1640 containing 1% BSA, 2.5 mM HEPES, and 0.05% NaN 3 . After incubation at 20°C with constant mixing for 1 h, the mixture was centrifuged through a 10% sucrose/PBS cushion and the cell-associated radioactivity was measured. Specific binding was documented as a percentage of 125 I-SDF-1␣ binding in the absence of unlabeled competitors.
RNA extraction and RT-PCR
Total RNA from purified human monocytes was extracted by using TRIzol Reagent (Invitrogen Life Technologies). RT-PCR was performed according to the specification of a Qiagen OneStep RT-PCR kit. Primer pairs for Robo (5Ј-TCC ACACAGCAATAGCGAAG-3Ј and 5Ј-GCCGCATCCGTATCCATATCT-3Ј), Slit1(5Ј-TGTTGCAGCTGATGGAGAAC-3Ј and 5Ј-TTCAGGGTCA GAACCTCCAG-3Ј), Slit2 (5Ј-TCAGTGGCAAGTTTCAACCA-3Ј and 5Ј-CTGTGATGGTCTCAGGCAGA-3Ј), Slit3 (5Ј-ACATCAGCCGTATCC TGGTC-3Ј and 5Ј-CCTGCAGGAATGGATTTGAT-3Ј), and Drm (5Ј-GCGAAGCTTATGAGCCGCACAGCCTAC-3Ј and 5Ј-ATTGTTAACTTA ATCCAAATCGATGGA-3Ј).
Statistical analysis
Each experiment was performed at least three times with similar results. Statistical comparison between two groups was conducted by Mann-Whitney U analysis.
Results and Discussion
Identification and characterization of Drm-Slits interaction
Screening ϳ1.5 ϫ 10 6 of cDNA using the yeast two-hybrid system yielded 25 clones that survived on HLT medium and had ␤-galactosidase expression. Rescreening revealed 21 plasmids containing authentic Drm-interacting components. Sequencing and BLAST search identified both Slit1 and Slit2 as Drm-interacting proteins (data not shown). To further confirm Drm-Slit interaction, we showed that Drm and Slits could be coimmunoprecipitated from the supernatants of mixed cultures of cells expressing Drm and myc-tagged Slit1 (Fig. 1a, lane 2) or from a lysate of coexpressing cells (Fig. 1a, lanes 4) . As controls, the supernatant (Fig. 1a, lane 1) or lysates (Fig. 1a, lanes 3 and  5) of cells expressing either Drm or Slit1 alone showed no evidence of association. Similarly, Drm could be precipitated from supernatant of cocultures of cells expressing both myc-tagged Slit2 and Drm (Fig. 1b, lane 4) by anti-myc tag antiserum, but not from the supernatant of vector-transfected cells (Fig. 1b,  lane 1) or from singly expressing cells (Fig. 1b, lanes 2 and 3) .
To analyze whether glycosylation of Drm might affect the interaction between Drm and Slit, we mutated Drm's glycosylation site (42NDS45E to 42IEA45E) (2) and investigated whether the mutation affected the interaction between Drm and Slit1. Mutated Drm could not be coprecipitated with myctagged Slit1 (Fig. 1c, lane 4) , suggesting that either glycosylation of Drm is necessary or Slit binding involves a site at or near the site of glycosylation. Since nonglycosylated Drm resulting from the same mutation is still able to bind BMPs and to interfere with BMP-mediated biological activity (2), it is unlikely that Drm's structure is drastically altered by the mutation per se or by the lack of glycosylation.
Drm has been shown to bind BMP2, 4, and 7 to subsequently block BMPs' ability to bind their receptors (2, 3, 12, 13). To determine whether the binding of BMP to Slits could affect the Drm-Slit interaction, we added exogenous BMP-4 or BMP-2 to conditioned medium containing Drm and Slit1 or Slit2 before immunoprecipitation. Exposure to 10 -100 nM of BMP-4 (Fig. 1d, left panel) for up to 48 h (Fig. 1d, right panel) failed to interfere with the coimmunoprecipitation of Drm and Slit1 (Fig. 1d) or Slit2 (data not shown). BMP-2 also did not interfere with Drm-Slit interaction (data not shown). These results provide further support for the notion that the region of Drm responsible for BMP binding is distinct from that interacting with Slits. 
Drm as negative regulator of monocyte chemotaxis
It has recently been reported that members of the Slit family of secreted guidance proteins, which regulate neuronal migration and axon growth (15, 16) via interaction with their cellular roundabout receptor (Robo), can also block leukocyte chemotaxis (17) . We investigated whether Drm could modulate the capacity of Slit2 to inhibit the chemotaxis of human monocytes in response to the chemokine SDF-1␣, using serum-free conditioned supernatants of Slit2-expressing HEK293 cells and Drm-expressing HT1080 cells as the sources of Slit2 and Drm, respectively. The chemotaxis of human monocytes in response to SDF-1␣ showed a bell-shaped dose-response curve, with an optimal concentration of SDF-1␣ at 100 ng/ml (Fig. 2a) . As previously reported (17) , Slit2 inhibited ϳ50% of the chemotaxis of monocytes in response to the optimal concentration of SDF-1␣ (Fig. 2b, third bar) . When added in combination with Slit2, Drm (Fig. 2b, fifth bar) , but not the control supernatant (Fig. 2b, fourth bar) , completely abrogated the chemotactic migration of monocytes induced by SDF-1␣. Similar to inhibiting SDF-1␣-induced monocyte chemotaxis, Drm also inhibited monocyte chemotaxis when fMLP was used as a chemotactic factor (Fig. 2c) , suggesting that Drm acted as an inhibitor of monocyte chemotaxis independent of the chemotactic factors used.
A combination of Drm and Slit2 almost completely inhibited the monocyte migration induced by either SDF-1␣ (Fig. 2b , fifth bar) or fMLP (Fig. 2c, fifth bar) suggested that either Drm enhanced the suppressive effect of Slit2 or Drm by itself exhibited a suppressive effect on monocyte chemotaxis. To distinguish between the two possibilities, we examined whether pure recombinant Drm could inhibit monocyte chemotaxis (Fig.  2d) . Drm dose-dependently inhibited the SDF-1␣-induced monocyte migration when present together with monocytes in the upper wells (Fig. 2d, fourth to seventh bars) , but not when present together with SDF-1␣ in the lower wells (Fig. 2d,  eighth bar) . Of note, Drm was not toxic for monocytes since coincubation of monocytes with Drm at even the highest concentration used for 1.5 h did not result in a loss of monocyte viability (data not shown), and Drm did not affect the background migration of monocytes (Fig. 2d, second bar) .
Dan interacts with Slits and acts as an inhibitor of monocyte chemotaxis
The Dan family contains at least seven members including Drm and Dan (2) (3) (4) 12) . To address whether acting as an inhibitor of monocyte chemotaxis is unique to Drm, we investigated whether Dan could also bind to Slits and inhibit SDF-1␣-induced chemotaxis of monocytes. Similar to Drm, Dan could interact with both Slit1 (lane 2) and Slit2 (lane 3) as demonstrated by coimmunoprecipitation and Western blotting (Fig.  3a) . Dan, when added simultaneously with monocytes to the upper wells of a chemotaxis chamber, also suppressed the chemotaxis of monocytes in a dose-dependent manner in response to an optimal concentration of SDF-1␣ with ϳ95% suppression at 2000 ng/ml (Fig. 3b) . The suppressive effect of Dan at 500 ng/ml on SDF-1␣-induced monocyte chemotaxis was dose-dependently neutralized by anti-Dan Ab (Fig. 3c) . The neutralization was ϳ90% and 100% at 2 and 10 g/ml antiDan Ab, while isotype-matched control Ab used at 10 g/ml had no effect (Fig. 3c) . Therefore, not only Drm but also Dan acts as an inhibitor of monocyte chemotaxis.
How does Dan or Drm inhibit monocyte chemotaxis? SDF-1␣ induces chemotaxis by binding to its receptor CXCR4, followed by the activation of a heterotrimeric G protein in target cells. Therefore, one possible mechanism by which Dan or Drm inhibits the chemotaxis of monocytes might simply be by abolishing the chemotactic activity of SDF-1␣. This appears unlikely because neither Drm (Fig. 2d) nor Dan (Fig.  3d) inhibited monocyte chemotaxis when added simultaneously with SDF-1␣ into the lower wells of the chemotaxis chamber. Another possibility might be by hindering the binding of SDF-1␣ to CXCR4 on target monocytes. However, as shown in Fig. 3e , Dan did not inhibit the binding of 125 I-SDF-1␣ to human monocytes, whereas unlabeled SDF-1␣ expectedly did so, suggesting that Dan's suppressive effect on SDF-1␣-induced monocyte chemotaxis is not due to competitive binding to the CXCR4 receptor. Since Slits can inhibit FIGURE 2. Drm suppression of monocyte chemotaxis. Chemotactic migration of human monocytes was measured using a 48-well microchemotaxis chamber assay. a, SDF-1␣ induced the migration of monocytes in a dose-dependent manner with an optimal dose at 100 ng/ml. b and c, Drm promotion of Slit2's suppressive effect on monocyte chemotaxis induced by SDF-1␣ (100 ng/ml) and fMLP (10 Ϫ8 M), respectively. Different combinations of conditioned medium from HEK293 cells stably expressing Slit2 or Drm were added with monocytes to the upper wells as indicated (final concentration, 20%). ‫ء‬ and ‡, p Ͻ 0.05 compared with the second and third bars, respectively. d, Inhibition of SDF-1␣ (100 ng/ml)-induced monocyte chemotaxis by Drm alone. Various concentrations of pure recombinant Drm (nanograms per milliliter) were added along with monocytes to the upper or lower wells of a chemotaxis chamber at concentrations as specified. ‫,ء‬ p Ͻ 0.05 compared with the third bar. monocyte chemotaxis by signaling through their receptor Robo (17) and both Drm and Dan can bind to Slit1 and Slit2 (Figs.  1 and 3a) , we hypothesized that the mechanism of Drm-or Dan-mediated inhibition of monocyte chemotaxis might be by promoting the suppressive effect of endogenous Slits. To search for support of this possibility, we determined whether monocytes express Slits and their receptor Robo by RT-PCR. The data demonstrated that monocytes express endogenous Slit1, Slit2, and Robo mRNA (Fig. 3f) .
Chemotaxis of leukocytes, including monocytes, is critical for the development of inflammation and immunity, yet past research has predominantly focused on chemoattraction and positive regulation of this process. To our knowledge, only Slit protein has previously been reported to act as negative regulator of chemotaxis (17) . The identification of Drm and Dan as Slitinteracting proteins and negative regulators of monocyte chemotaxis not only reveals a novel function beyond their roles as BMP antagonists but also broadens the search for chemotaxis inhibitors. Further elucidation of the signaling mechanism(s) responsible for Drm-and/or Dan-mediated inhibition of monocyte chemotaxis may provide useful clues for the design of potential therapeutic inhibitor(s) that attenuate leukocyte migration for the treatment of autoimmunity, inflammation, HIV infection, cancer, and other diseases.
